Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 20/20 | 0.85 |
| ▸ | JAK2 | O60674 | 10/20 | 0.85 |
| ▸ | JAK1 | P23458 | 10/20 | 0.85 |
| ▸ | TYK2 | P29597 | 5/20 | 0.85 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.85 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.85 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.85 |
| ▸ | STK3 | Q13188 | 3/20 | 0.85 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.85 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.85 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.85 |
| ▸ | MARK3 | P27448 | 2/20 | 0.85 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.85 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.85 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.85 |
| ▸ | ABL1 | P00519 | 2/20 | 0.85 |
| ▸ | LCK | P06239 | 2/20 | 0.85 |
| ▸ | FYN | P06241 | 2/20 | 0.85 |
| ▸ | RET | P07949 | 2/20 | 0.85 |
| ▸ | DMPK | Q09013 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065509 | 1.00 | JAK3 (0.85) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL16937876 | 1.00 | JAK3 (0.85) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL322753 | 0.92 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tasocitinib SCHEMBL30341861 | 0.92 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL29351183 | 0.92 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL23199919 | 0.92 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tasocitinib SCHEMBL23058868 | 0.92 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL29816283 | 0.92 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL28416782 | 0.92 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL30925309 | 0.92 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9050342-B2 | Beneficial effects of combination therapy on cholesterol | PFIZER INC. (US) | 2015-06-09 | — | — | US | claimed |
| US-20120252825-A1 | BENEFICIAL EFFECTS OF COMBINATION THERAPY ON CHOLESTEROL | PFIZER INC. (US) | 2012-10-04 | — | — | US | claimed |
| WO-2008029237-A2 | COMBINATION THERAPIES FOR RHEUMATOID ARTHRITIS | PFIZER PRODUCTS INC. (US) | 2008-03-13 | — | — | WO | claimed |
| US-7250420-B2 | Method of treatment of transplant rejection | PFIZER INC. (US) | 2007-07-31 | — | — | US | claimed |
| EP-1734967-A2 | PYRROLO [2,3-D] PYRIMIDINE COMPOUNDS FOR TREATING TRANSPLANT REJECTION | Pfizer Products Incorporated (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1689407-A1 | METHOD OF TREATMENT OF ATHEROSCLEROSIS | Pfizer Products Inc. (US) | 2006-08-16 | — | — | EP | claimed |
| EP-1572213-A1 | METHOD OF TREATMENT OF TRANSPLANT REJECTION | Pfizer Products Inc. (US) | 2005-09-14 | — | — | EP | claimed |
| US-20050159433-A1 | Method treatment of transplant rejection | PFIZER INC | 2005-07-21 | — | — | US | claimed |
| WO-2005063251-A1 | MODIFIED STENT USEFUL FOR DELIVERY OF DRUGS ALONG STENT STRUT | PFIZER PRODUCTS INC. (US) | 2005-07-14 | — | — | WO | claimed |
| WO-2005060972-A2 | PYRROLO [2,3-D] PYRIMIDINE COMPOUNDS FOR TREATING TRANSPLANT REJECTION | PFIZER PRODUCTS INC. (US) | 2005-07-07 | — | — | WO | claimed |
| US-20050137679-A1 | Modified stent useful for delivery of drugs along stent strut | PFIZER INC | 2005-06-23 | — | — | US | claimed |
| WO-2005051393-A1 | METHOD OF TREATMENT OF ATHEROSCLEROSIS | PFIZER PRODUCTS INC. (US) | 2005-06-09 | — | — | WO | claimed |
| US-20040229923-A1 | Chiral salt resolution | PFIZER INC. | 2004-11-18 | — | — | US | claimed |
| US-20040116449-A1 | Method of treatment of transplant rejection | PFIZER INC | 2004-06-17 | — | — | US | claimed |
| WO-2004047843-A1 | METHOD OF TREATMENT OF TRANSPLANT REJECTION | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | claimed |
| US-20030073719-A1 | Chiral salt resolution | PFIZER INC. | 2003-04-17 | — | — | US | claimed |
| US-9050342-B2 | Beneficial effects of combination therapy on cholesterol | PFIZER INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20130338168-A1 | Combinations of JAK Inhibitors | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| WO-2004047843-A1 | METHOD OF TREATMENT OF TRANSPLANT REJECTION | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20030073719-A1 | Chiral salt resolution | PFIZER INC. | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229923-A1 | Chiral salt resolution | REN, SRR, RER1 | JAK3 4250/4885JAK2 3069/4885JAK1 3549/4885 |
| US-20030073719-A1 | Chiral salt resolution | REN, SRR, RER1 | JAK3 4250/4885JAK2 3069/4885JAK1 3549/4885 |
| US-20050159433-A1 | Method treatment of transplant rejection | ARG1, TST, CD74 | JAK3 1530/4885JAK2 2735/4885JAK1 1850/4885 |
| US-20130338168-A1 | Combinations of JAK Inhibitors | JAK2, JAK3, JAK1 | JAK3 2/4885JAK2 1/4885JAK1 3/4885 |
| US-20120252825-A1 | BENEFICIAL EFFECTS OF COMBINATION THERAPY ON CHOLESTEROL | HMGCR, LDLR, PCSK9 | JAK3 102/4885JAK2 87/4885JAK1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.